α2C-adrenergic receptors mediate spinal analgesia and adrenergic-opioid synergy

被引:152
作者
Fairbanks, CA
Stone, LS
Kitto, KF
Nguyen, HO
Posthumus, IJ
Wilcox, GL
机构
[1] Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Dept Neurosci, Minneapolis, MN 55455 USA
关键词
D O I
10.1124/jpet.300.1.282
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The alpha(2A)-adrenergic receptor (AR) subtype mediates antinociception induced by the alpha(2)AR agonists clonidine, dexmedetomidine, norepinephrine, and 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine (UK-14,304) as well as antinociceptive synergy of UK-14,304 with opioid agonists [D-Ala(2),N-Me-Phe(4),Gly(5)-ol]-enkephalin and deltorphin II. Differential localization of alpha(2)-adrenergic (alpha(2A)-, alpha(2B)-, alpha(2C)-) and opioid (mu-, delta-, kappa-) subtypes suggests differential involvement of subtype pairs in opioid-adrenergic analgesic synergy. The present study applies a novel imidazoline(1)/alpha(2)-adrenergic receptor analgesic, moxonidine, to test for involvement of alpha(2B)- and alpha(2C)ARs in antinociception and antinociceptive synergy, because spinal antinociceptive activity of moxonidine shows minimal dependence on alpha(2A)AR. Intrathecal administration of moxonidine produced similar (2-3-fold) decreases in both mutant mice with a functional knockout of alpha(2A)AR (D79N-alpha(2A)AR) and alpha(2C)AR knockout (KO) mice. The potency of moxonidine was not altered in alpha(2B)KO mice, indicating that this subtype does not participate in moxonidine-induced spinal antinociception. Moxonidine-mediated antinociception was dose dependently inhibited by the selective alpha(2)-receptor antagonist SK&F 86466 in both D79N-alpha(2A) mice and a,,KO mice, indicating that a2AR activation is required in the absence of either alpha(2A)- or alpha(2C)AR. Spinal administration of antisense oligodeoxynucleotides directed against the alpha(2C)AR decreased both alpha(2C)AR immunoreactivity and the antinociceptive potency of moxonidine. Isobolographic analysis demonstrates that moxonidine-deltorphin antinociceptive synergy is present in the D79N-alpha(2A) mice but not in the alpha(2C)AR-KO mice. These results confirm that the a,,AR subtype contributes to spinal antinociception and synergy with opioids.
引用
收藏
页码:282 / 290
页数:9
相关论文
共 49 条
  • [21] Cardiovascular regulation in mice lacking alpha(2)-adrenergic receptor subtypes b and c
    Link, RE
    Desai, K
    Hein, L
    Stevens, ME
    Chruscinski, A
    Bernstein, D
    Barsh, GS
    Kobilka, BK
    [J]. SCIENCE, 1996, 273 (5276) : 803 - 805
  • [22] MacDonald E, 1997, TRENDS PHARMACOL SCI, V18, P211
  • [23] Central hypotensive effects of the alpha(2a)-adrenergic receptor subtype
    MacMillan, LB
    Hein, L
    Smith, MS
    Piascik, MT
    Limbird, LE
    [J]. SCIENCE, 1996, 273 (5276) : 801 - 803
  • [24] Role of the α2B-adrenergic receptor in the development of salt-induced hypertension
    Makaritsis, KP
    Handy, DE
    Johns, C
    Kobilka, B
    Gavras, I
    Gavras, H
    [J]. HYPERTENSION, 1999, 33 (01) : 14 - 17
  • [25] Antisense technology reveals the alpha(2A) adrenoceptor to be the subtype mediating the hypnotic response to the highly selective agonist, dexmedetomidine, in the locus coeruleus of the rat
    Mizobe, T
    Maghsoudi, K
    Sitwala, K
    Tianzhi, G
    Ou, J
    Maze, M
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (05) : 1076 - 1080
  • [26] DISTRIBUTIONS OF MESSENGER-RNAS FOR ALPHA-2 ADRENERGIC-RECEPTOR SUBTYPES IN RAT-BRAIN - AN INSITU HYBRIDIZATION STUDY
    NICHOLAS, AP
    PIERIBONE, V
    HOKFELT, T
    [J]. JOURNAL OF COMPARATIVE NEUROLOGY, 1993, 328 (04) : 575 - 594
  • [27] INHIBITORY EFFECTS OF CLONIDINE AND TIZANIDINE ON RELEASE OF SUBSTANCE-P FROM SLICES OF RAT SPINAL-CORD AND ANTAGONISM BY ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS
    ONO, H
    MISHIMA, A
    ONO, S
    FUKUDA, H
    VASKO, MR
    [J]. NEUROPHARMACOLOGY, 1991, 30 (06) : 585 - 589
  • [28] ROERIG SC, 1992, J PHARMACOL EXP THER, V262, P365
  • [29] Insights from in vivo modification of adrenergic receptor gene expression
    Rohrer, DK
    Kobilka, BK
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1998, 38 : 351 - 373
  • [30] Rosin DL, 1998, J COMP NEUROL, V401, P163